
Drug Approvals
European Commission Approves SPEVIGO® (spesolimab) for Generalized Pustular Psoriasis (GPP) Flares
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients